Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast

Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib

Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

October 18, 2025 - Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies

for oncology, today announced detailed efficacy and safety results from the PIK3CA wild-type ("WT") cohort of the

Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in adults with hormone receptor positive

("HR+"), human epidermal growth factor receptor 2 negative ("HER2-"), PIK3CA WT, advanced breast cancer

("ABC"), following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor. As previously

announced, the gedatolisib triplet demonstrated a statistically significant and clinically meaningful improvement in median progression-free

survival ("PFS") versus fulvestrant, reducing the risk of disease progression or death by 76%. The gedatolisib doublet reduced

the risk of progression or death by 67% versus fulvestrant.

detailed study results were presented at a late breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress

today, Saturday, October 18 at 4:25 a.m. ET/10:25 a.m. CEST.

the trial, median PFS with the gedatolisib triplet was 9.3 months versus 2.0 months with fulvestrant, an incremental improvement of 7.3

months (HR=0.24; 95% CI: 0.17-0.35; p<0.0001). The objective response rate ("ORR") of the gedatolisib triplet was 31.5%

compared to 1% with fulvestrant and the median duration of response ("DOR") was 17.5 months. For the gedatolisib doublet,

the median PFS was 7.4 months versus 2.0 months with fulvestrant, an incremental improvement of 5.4 months (HR=0.33; 95% CI: 0.24-0.48;

p<0.0001). The ORR of the gedatolisib doublet was 28.3% and the median DOR was 12.0 months. The median DOR was not determinable for

fulvestrant because there was only one objective response.

topline efficacy data from the VIKTORIA-1 PIK3CA WT cohort established several new milestones in the history of drug development

median PFS benefit of the gedatolisib triplet and doublet compared to fulvestrant was consistent across subgroups with the gedatolisib

triplet showing higher clinical benefit in nearly all subgroups compared to the gedatolisib doublet, particularly for patients who were

pre/perimenopausal, endocrine therapy resistant, or had visceral metastases. For patients enrolled in the United States and Canada, median

PFS was 19.3 months (HR=0.13; 90% CI: 0.07-0.29) for the gedatolisib triplet and 14.9 months (HR=0.35; 90% CI: 0.17-0.76) for the gedatolisib

Hurvitz, MD, Senior Vice President, Clinical Research Division, Fred Hutchinson Cancer Center, Smith Family Endowed Chair in Women's

Health, Professor and Head, Division of Hematology and Oncology, University of Washington, Department of Medicine and co-principal investigator

for the trial, said: "VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement

in median PFS with inhibition of the PI3K/AKT/mTOR pathway in patients with PIK3CA wild-type disease, all of whom previously received

a CDK4/6 inhibitor. With these results, the gedatolisib regimens represent a new potential standard of care for patients with HR+, HER2-negative,

PIK3CA wild-type advanced breast cancer whose disease progressed on or after treatment with a CDK4/6 inhibitor."

gedatolisib triplet and doublet were generally well tolerated in the trial with mostly low-grade treatment-related adverse events ("TRAEs").

The most common grade 3 TRAEs for the gedatolisib triplet, gedatolisib doublet, and fulvestrant groups included neutropenia (52.3%, 0%,

and 0.8% of patients, respectively); stomatitis (19.2%, 12.3%, and 0%) rash (4.6%, 5.4%, and 0%); and hyperglycemia (2.3%, 2.3%, and

0%). The primary grade 4 TRAEs for the gedatolisib triplet and gedatolisib doublet groups were neutropenia (10.0% and 0.8%, respectively),

leukopenia (0.8% in the gedatolisib triplet group) and pneumonitis (0.8% in gedatolisib doublet group). TRAEs led to the discontinuation

of study treatment in 2.3% of patients in the gedatolisib triplet group, 3.1% in the gedatolisib doublet group, and 0% in the fulvestrant

survival, a key secondary endpoint in VIKTORIA-1, while immature at the time of the analysis, with less than one-half of the required

number of events having occurred, showed promising trends for both the gedatolisib triplet and doublet.

Gorbatchevsky, MD, Chief Medical Officer of Celcuity, said: "We are very excited that treatment with gedatolisib combined with

fulvestrant with or without palbociclib was well-tolerated by the VIKTORIA-1 patients and that only a few patients discontinued treatment

due to an adverse event. This safety profile combined with the 7.3 and 5.4-months incremental improvement in median PFS relative to fulvestrant

for the gedatolisib regimens, offer potentially paradigm shifting results for patients with HR-positive, HER2-negative, PIK3CA

wild-type advanced breast cancer."

initiated a rolling New Drug Application ("NDA") submission in conjunction with the U.S. Food and Drug Administration's

("FDA") Real-Time Oncology Review program, based on data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1

clinical trial. Completion of the NDA submission is targeted for the fourth quarter of 2025. The PIK3CA mutant cohort of the Phase

3 VIKTORIA-1 trial is 100% enrolled and is expected to report topline data for this cohort in late Q1 2026 or during Q2 2026.

and Conference Call Information

Celcuity management team will host a webcast/conference call on Monday, October 20, 2025, at 8:00 a.m. ET to discuss the additional results

from the Phase 3 VIKTORIA-1 trial. Those who would like to participate may access the live webcast here or register in advance

for the teleconference here. A replay of the webcast will be available on the Celcuity website following the live event.

cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide.1 More than two million

breast cancer cases were diagnosed globally in 2022.1 While survival rates are high for those diagnosed with early breast

cancer, approximately 30% of patients who are diagnosed with or who progress to metastatic disease are expected to live five years after

their diagnosis.2 HR+/HER2- breast cancer is the most common subtype of breast cancer, accounting for approximately 70% of

all breast cancers.2

interconnected signaling pathways, estrogen, cyclin D1-CDK4/6, and PI3K/AKT/mTOR (PAM), are primary oncogenic drivers of HR+, HER2- breast

cancer.3 Therapies inhibiting these pathways are approved and used in various combinations for advanced breast cancer. Currently

approved inhibitors of the PAM pathway for breast cancer target a single PAM pathway component, such as PI3K , AKT, or mTORC1.4,5,6,7

However, resistance to CDK4/6 inhibitors and current endocrine therapies develops in many patients with advanced disease.8

Optimizing the inhibition of the PAM pathway is an active area of focus for breast cancer research.

is a Phase 3 open-label, randomized clinical trial to evaluate the efficacy and safety of gedatolisib in combination with fulvestrant

with or without palbociclib in adults with HR+/HER2- ABC whose disease progressed on or after prior CDK4/6 therapy in combination with

an aromatase inhibitor. The clinical trial is fully enrolled. The trial enrolled subjects regardless of PIK3CA status while enabling

separate evaluation of subjects according to their PIK3CA status. Subjects who met eligibility criteria and did not have confirmed

PI3KCA mutations (WT) were randomly assigned (1:1:1) to receive a regimen of either gedatolisib, palbociclib, and fulvestrant,

gedatolisib and fulvestrant, or fulvestrant. Subjects who met eligibility criteria and had confirmed PI3KCA mutations (MT) were

randomly assigned (3:3:1) to receive a regimen of either the gedatolisib triplet, alpelisib and fulvestrant, or the gedatolisib doublet.

is an investigational, multi-target PAM inhibitor that potently targets all four class I PI3K isoforms, mTORC1, and mTORC2 to induce

comprehensive blockade of the PAM pathway.9,10,11 As a multi-target PAM inhibitor, gedatolisib's mechanism of action

is highly differentiated from currently approved single-target inhibitors of the PAM pathway.11 Inhibition of only a single

PAM component gives tumors an escape mechanism through cross-activation of the uninhibited targets. Gedatolisib's comprehensive

PAM pathway inhibition ensures full suppression of PAM activity by eliminating adaptive resistance cross-activation that occurs with

single-target inhibitors. Unlike single-target inhibitors of the PAM pathway, gedatolisib has demonstrated equal potency and comparable

cytotoxicity in PIK3CA-mutant and wild-type breast tumor cells in nonclinical studies and early clinical data.11,12

is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications.

The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades

the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational

therapies that target PI3K , AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in

combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC has completed enrollment and reported topline

data for the PIK3CA WT cohort and has completed enrollment of patients for the PIK3CA mutant cohort. A Phase 3 clinical

trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2-

ABC is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide

in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity's active

clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity

press release contains statements that constitute "forward-looking statements" within the meaning of the Private Securities

Litigation Reform Act of 1995 including statements relating to the potential therapeutic benefits of gedatolisib; the size, design and

timing of our clinical trials; our interpretation of topline clinical trial data; and other expectations with respect to gedatolisib.

Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate,"

"estimate," "intend," "confidence," "encouraged," "potential," "plan,"

"targets," "likely," "may," "will," "would," "should" and "could,"

and similar expressions or words identify forward-looking statements. The forward-looking statements included in this press release are

based on management's current expectations and beliefs which are subject to a number of risks, uncertainties and factors, including

that our topline results are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more

comprehensive review of the data related to the clinical trial; unforeseen delays in our clinical trials; and unanticipated developments

that may impact the design of our clinical trials. In addition, all forward-looking statements are subject to other risks detailed in

our Annual Report on Form 10-K for the year ended December 31, 2024, as such risks may be updated in our subsequent filings with the

Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only

as of the date hereof. All forward-looking statements are qualified in their entirety by these cautionary statements, and we undertake